WO2004059293A3 - Markers for differential diagnosis and methods of use thereof - Google Patents

Markers for differential diagnosis and methods of use thereof Download PDF

Info

Publication number
WO2004059293A3
WO2004059293A3 PCT/US2003/041453 US0341453W WO2004059293A3 WO 2004059293 A3 WO2004059293 A3 WO 2004059293A3 US 0341453 W US0341453 W US 0341453W WO 2004059293 A3 WO2004059293 A3 WO 2004059293A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
differential diagnosis
markers
diseases
compositions
Prior art date
Application number
PCT/US2003/041453
Other languages
French (fr)
Other versions
WO2004059293A2 (en
Inventor
Kenneth F Buechler
Alan Maisel
Joseph Michael Anderberg
Paul H Mcpherson
Jeffrey R Dahlen
Howard J Kirchick
Original Assignee
Biosite Inc
Kenneth F Buechler
Alan Maisel
Joseph Michael Anderberg
Paul H Mcpherson
Jeffrey R Dahlen
Howard J Kirchick
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/330,696 external-priority patent/US7713705B2/en
Priority claimed from US10/371,149 external-priority patent/US20030199000A1/en
Priority claimed from US10/603,891 external-priority patent/US20040253637A1/en
Priority claimed from US10/673,077 external-priority patent/US20040209307A1/en
Priority claimed from US10/714,078 external-priority patent/US20040219509A1/en
Priority to CA002511501A priority Critical patent/CA2511501A1/en
Priority to AU2003302340A priority patent/AU2003302340B8/en
Application filed by Biosite Inc, Kenneth F Buechler, Alan Maisel, Joseph Michael Anderberg, Paul H Mcpherson, Jeffrey R Dahlen, Howard J Kirchick filed Critical Biosite Inc
Priority to EP03810896A priority patent/EP1587955A4/en
Priority to JP2005510072A priority patent/JP2006526140A/en
Publication of WO2004059293A2 publication Critical patent/WO2004059293A2/en
Publication of WO2004059293A3 publication Critical patent/WO2004059293A3/en
Priority to IL169348A priority patent/IL169348A0/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4737—C-reactive protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Brain natriuretic peptide [BNP, proBNP]; Cardionatrin; Cardiodilatin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/9123—Phosphotransferases in general with a nitrogenous group as acceptor (2.7.3), e.g. histidine kinases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96486—Metalloendopeptidases (3.4.24)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/974—Thrombin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2871—Cerebrovascular disorders, e.g. stroke, cerebral infarct, cerebral haemorrhage, transient ischemic event

Abstract

The present invention provides methods for the identification and use of diagnostic markers for differential diagnosis of diseases and/or conditions. In a various aspects, the invention relates to methods and compositions able to determine the presence or absence of one, and preferably a plurality, of diseases or conditions that exhibit one or more similar or identical symptoms. Such methods and compositions can be used to provide assays and assay devices for use in determining the disease or condition underlying one or more non-specific symptoms exhibited in a clinical setting.
PCT/US2003/041453 2002-12-24 2003-12-23 Markers for differential diagnosis and methods of use thereof WO2004059293A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2005510072A JP2006526140A (en) 2002-12-24 2003-12-23 Marker for differential diagnosis and method of using the same
EP03810896A EP1587955A4 (en) 2002-12-24 2003-12-23 Markers for differential diagnosis and methods of use thereof
CA002511501A CA2511501A1 (en) 2002-12-24 2003-12-23 Markers for differential diagnosis and methods of use thereof
AU2003302340A AU2003302340B8 (en) 2002-12-24 2003-12-23 Markers for differential diagnosis and methods of use thereof
IL169348A IL169348A0 (en) 2002-12-24 2005-06-23 Markers for differential diagnosis and methods of use thereof

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US43630102P 2002-12-24 2002-12-24
US60/436,301 2002-12-24
US10/330,696 US7713705B2 (en) 2002-12-24 2002-12-27 Markers for differential diagnosis and methods of use thereof
US10/330,696 2002-12-27
US10/371,149 2003-02-20
US10/371,149 US20030199000A1 (en) 2001-08-20 2003-02-20 Diagnostic markers of stroke and cerebral injury and methods of use thereof
US10/603,891 2003-06-24
US10/603,891 US20040253637A1 (en) 2001-04-13 2003-06-24 Markers for differential diagnosis and methods of use thereof
US10/673,077 US20040209307A1 (en) 2001-08-20 2003-09-26 Diagnostic markers of stroke and cerebral injury and methods of use thereof
US10/673,077 2003-09-26
US10/714,078 US20040219509A1 (en) 2001-08-20 2003-11-14 Diagnostic markers of stroke and cerebral injury and methods of use thereof
US10/714,078 2003-11-14

Publications (2)

Publication Number Publication Date
WO2004059293A2 WO2004059293A2 (en) 2004-07-15
WO2004059293A3 true WO2004059293A3 (en) 2005-03-31

Family

ID=32686403

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/041453 WO2004059293A2 (en) 2002-12-24 2003-12-23 Markers for differential diagnosis and methods of use thereof

Country Status (5)

Country Link
EP (1) EP1587955A4 (en)
JP (1) JP2006526140A (en)
AU (1) AU2003302340B8 (en)
CA (1) CA2511501A1 (en)
WO (1) WO2004059293A2 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7838250B1 (en) 2006-04-04 2010-11-23 Singulex, Inc. Highly sensitive system and methods for analysis of troponin
US8221995B2 (en) 2007-03-23 2012-07-17 Seok-Won Lee Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes
US8450069B2 (en) 2009-06-08 2013-05-28 Singulex, Inc. Highly sensitive biomarker panels
US9494598B2 (en) 2006-04-04 2016-11-15 Singulex, Inc. Highly sensitive system and method for analysis of troponin

Families Citing this family (125)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7713705B2 (en) 2002-12-24 2010-05-11 Biosite, Inc. Markers for differential diagnosis and methods of use thereof
MXPA03004105A (en) 2002-05-14 2004-10-15 Hoffmann La Roche Making a prognosis in cases of cardiac disease using a combination of markers.
JP2006506069A (en) 2002-11-12 2006-02-23 ベクトン，ディッキンソン アンド カンパニー Diagnosis of sepsis or SIRS using biomarker profiles
JP4643445B2 (en) 2002-11-12 2011-03-02 ベクトン，ディッキンソン アンド カンパニー Diagnosis of sepsis or SIRS using biomarker profiles
EP1519194A1 (en) * 2003-09-24 2005-03-30 Roche Diagnostics GmbH Use of gfap for identification of intracerebral hemorrhage
US20050196817A1 (en) 2004-01-20 2005-09-08 Molecular Staging Inc. Biomarkers for sepsis
US8492107B2 (en) 2004-04-15 2013-07-23 University Of Florida Research Foundation, Inc. Neural proteins as biomarkers for nervous system injury and other neural disorders
ES2391097T3 (en) * 2004-04-26 2012-11-21 Janssen Biotech, Inc. Panning procedure in solution using genetically modified decoy proteins
EP2258866A3 (en) 2004-07-23 2011-03-30 AspenBio Pharma, Inc. Methods and devices for diagnosis of appendicitis
US7659087B2 (en) 2004-07-23 2010-02-09 Aspenbio Pharma, Inc. Methods and devices for diagnosis of appendicitis
DE102004041659A1 (en) * 2004-08-27 2006-03-02 Institut Virion/Serion Gmbh Test device for the in vitro diagnosis of multi-analyte tests and their use
ITFI20040243A1 (en) * 2004-11-25 2005-02-25 Paola Romagnani DIAGNOSTIC METHOD FOR REJECTION OF TRANSPLANTED ORGAN
JP4828550B2 (en) * 2005-02-17 2011-11-30 エフ．ホフマン−ラ ロシュ アーゲー Use of the NT-proANP / NT-proBNP ratio to diagnose cardiac dysfunction
WO2006113529A2 (en) 2005-04-15 2006-10-26 Becton, Dickinson And Company Diagnosis of sepsis
US20070269836A1 (en) * 2005-06-09 2007-11-22 Mcpherson Paul H Methods and compositions for the diagnosis of venous thromboembolic disease
US20070099239A1 (en) * 2005-06-24 2007-05-03 Raymond Tabibiazar Methods and compositions for diagnosis and monitoring of atherosclerotic cardiovascular disease
CN101268369A (en) * 2005-06-29 2008-09-17 儒勒斯贝斯特医药有限公司 Methods and kits for the diagnosis of acute coronary syndrome
JP2009500040A (en) * 2005-07-08 2009-01-08 フイラデルフイア・ヘルス・アンド・エデユケーシヨン・コーポレーシヨン・デイー／ビー／エイ ドレクセルユニバーシテイカレツジオブメデイシン Methods for monitoring neuro-inflammatory destruction of neurons and methods for treating diseases with inflammatory components associated with phospholipase A2
US20090226898A1 (en) * 2005-07-14 2009-09-10 Inverness Medical Switzerland Gmbh Mitochondrial markers of ischemia
DE102005034174A1 (en) * 2005-07-21 2007-02-08 B.R.A.H.M.S Ag CSF in vitro diagnostic procedure for dementia and neuroinflammatory diseases
DE102005036094A1 (en) * 2005-08-01 2007-02-08 B.R.A.H.M.S Ag In vitro method for the diagnosis of neurodegenerative diseases
JP2007082433A (en) * 2005-09-20 2007-04-05 Niigata Univ Malignant brain tumor marker gene and use of the same
WO2007041645A2 (en) * 2005-10-03 2007-04-12 Scios Inc. Oxidized human bnp
JP2009525462A (en) * 2005-12-15 2009-07-09 ベクトン・ディキンソン・アンド・カンパニー Diagnosis of sepsis
EP1845379A1 (en) * 2006-04-13 2007-10-17 F. Hoffmann-La Roche AG Means and methods for the differentiation of cardiac and pulmonary causes of shortness of breath
EP2021495A4 (en) 2006-05-09 2009-06-24 Musc Found For Res Dev Detecting diastolic heart failure by protease and protease inhibitor plasma profiling
DE102006023175A1 (en) 2006-05-17 2007-11-22 B.R.A.H.M.S Aktiengesellschaft In vitro diagnostic and early diagnosis of neurodegenerative diseases
DE102006027818A1 (en) * 2006-06-16 2007-12-20 B.R.A.H.M.S. Aktiengesellschaft In vitro multiparameter determination method for the diagnosis and early diagnosis of neurodegenerative diseases
DE102006034142A1 (en) * 2006-07-24 2008-01-31 B.R.A.H.M.S. Aktiengesellschaft Method for controlling the therapy of heart failure patients by the in vitro determination of threshold levels of vasoactive peptides
EP1882947A1 (en) * 2006-07-28 2008-01-30 F. Hoffmann-La Roche AG Means and methods for the differentation of cardiac and pulmonary causes of acute shortness of breath
ATE511656T1 (en) * 2006-08-04 2011-06-15 Hannover Med Hochschule METHOD FOR RISK ASSESSMENT OF CARDIAC PROCEDURES BASED ON GDF-15
JP5244103B2 (en) * 2006-08-09 2013-07-24 ホームステッド クリニカル コーポレイション Organ-specific protein and method of use thereof
EP1909206A1 (en) 2006-09-11 2008-04-09 Roche Diagnostics GmbH Improvement of measuring range of a chromatographic rapid test
EP1901072B1 (en) * 2006-09-15 2009-11-25 F. Hoffman-la Roche AG Biochemical markers for acute pulmonary embolism
US8449864B2 (en) 2006-10-20 2013-05-28 The Board Of Trustees Of The Leland Stanford Junior University Neurotensin as a marker and therapeutic target for sepsis
DE102006053442A1 (en) * 2006-11-12 2008-05-15 Brahms Aktiengesellschaft Diagnosis and risk stratification of infections and chronic diseases of the respiratory and lungs by means of proVasopressin, in particular copeptin or neurophysin II
EP2095106B1 (en) 2006-11-14 2013-03-20 Alere San Diego, Inc. Methods and compositions for diagnosis and prognosis of renal artery stenosis
WO2008060607A2 (en) 2006-11-14 2008-05-22 Biosite Incorporated Methods and compositions for monitoring and risk prediction in cardiorenal syndrome
SE532103C2 (en) 2006-12-12 2009-10-27 Knut Johansen Method for determining the health status of analytes in liquid samples
DE102007022367A1 (en) * 2007-05-07 2008-11-20 B.R.A.H.M.S Ag Method for the determination of amino-terminal pro-ANP in overweight patients
US9884899B2 (en) 2007-07-06 2018-02-06 Promedior, Inc. Methods for treating fibrosis using CRP antagonists
EP2019318A1 (en) * 2007-07-27 2009-01-28 Erasmus University Medical Center Rotterdam Protein markers for cardiovascular events
EP2293078B1 (en) 2007-08-03 2011-11-09 B.R.A.H.M.S GmbH Method for diagnosis of a bacterial infection
EP2020603A1 (en) * 2007-08-03 2009-02-04 BRAHMS Aktiengesellschaft Method for risk stratification in stable coronary artery disease
US8431367B2 (en) 2007-09-14 2013-04-30 Predictive Biosciences Corporation Detection of nucleic acids and proteins
US20090075266A1 (en) * 2007-09-14 2009-03-19 Predictive Biosciences Corporation Multiple analyte diagnostic readout
EP2031397A1 (en) 2007-08-30 2009-03-04 F. Hoffmann-La Roche AG Surfactant proteins B and D in differentiating the causes of shortness of breath
US7955822B2 (en) 2007-09-14 2011-06-07 Predictive Biosciences Corp. Detection of nucleic acids and proteins
US8852893B2 (en) 2007-09-14 2014-10-07 Physicians Choice Laboratory Services, Llc Detection of nucleic acids and proteins
EP2225559B8 (en) 2007-12-28 2016-12-21 F. Hoffmann-La Roche AG Assessment of physiological conditions
JP5663314B2 (en) * 2008-03-04 2015-02-04 リッジ ダイアグノスティックス，インコーポレイテッド Diagnosis and monitoring of depression based on multiple biomarker panels
CA2718251A1 (en) * 2008-03-10 2009-09-17 Lineagen, Inc. Copd biomarker signatures
JP5658571B2 (en) * 2008-03-12 2015-01-28 リッジ ダイアグノスティックス，インコーポレイテッド Inflammatory biomarkers for monitoring depression disorders
US7776522B2 (en) 2008-04-24 2010-08-17 Becton, Dickinson And Company Methods for diagnosing oncogenic human papillomavirus (HPV)
JP2011528115A (en) * 2008-07-14 2011-11-10 エフ．ホフマン−ラ ロシュ アーゲー Multi-marker panel for diagnosis, monitoring and treatment selection of patients with heart failure
CA2732201A1 (en) * 2008-08-13 2010-02-18 F. Hoffmann-La Roche Ag D-dimer, troponin, nt-probnp for pulmonary embolism
EP2166358A1 (en) * 2008-09-17 2010-03-24 Fundacio Institut de Recerca de l'Hospital Universitari Vall d'Hebron Differential diagnostic biomarkers of stroke mimicking conditions and methods of use thereof
JP5219048B2 (en) * 2008-09-17 2013-06-26 独立行政法人農業・食品産業技術総合研究機構 Method for evaluating animal stress using anti-porcine interleukin-18 antibody
WO2010046136A1 (en) * 2008-10-24 2010-04-29 B.R.A.H.M.S. Ag Prognosis and risk assessment in stroke patients by determining the level of marker peptides
JP5767973B2 (en) * 2008-11-18 2015-08-26 リッジ ダイアグノスティックス，インコーポレイテッド Metabolic syndrome biomarker and HPA axis biomarker for major depressive disorder
CA2754961C (en) 2009-03-11 2018-04-10 Promedior, Inc. Treatment and diagnostic methods for hypersensitive disorders
AU2010224172B2 (en) 2009-03-11 2016-01-21 Promedior, Inc. Treatment methods for autoimmune disorders
KR20180018833A (en) 2009-05-11 2018-02-21 베르그 엘엘씨 Methods for treatment of oncological disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers
UA110323C2 (en) 2009-06-04 2015-12-25 Promedior Inc Derivative of serum amyloid p and their receipt and application
WO2011006119A2 (en) 2009-07-09 2011-01-13 The Scripps Research Institute Gene expression profiles associated with chronic allograft nephropathy
US20120149131A1 (en) 2009-08-28 2012-06-14 B.R.A.H.M.S Gmbh Procalcitonin for the prognosis of adverse events
AU2010291933B2 (en) 2009-09-14 2016-09-08 Banyan Biomarkers, Inc. Micro-RNA, autoantibody and protein markers for diagnosis of neuronal injury
KR20120123056A (en) 2009-12-20 2012-11-07 아스튜트 메디컬 인코포레이티드 Methods and compositions for diagnosis and prognosis of renal injury and renal failure
MX366653B (en) * 2010-02-05 2019-07-17 Astute Medical Inc METHODS and COMPOSITIONS FOR DIAGNOSIS and PROGNOSIS OF RENAL INJURY and RENAL FAILURE.
RU2580278C2 (en) * 2010-03-08 2016-04-10 Б.Р.А.Х.М.С Гмбх Pro-calcitonin for diagnosis of bacterial infections and control of antibiotic treatment for patients with nonspecific complaints
CA2793216C (en) 2010-03-22 2020-01-07 Stemina Biomarker Discovery, Inc. Predicting human developmental toxicity of pharmaceuticals using human stem-like cells and metabolomics
AU2011248464B2 (en) 2010-04-29 2016-08-11 Stemina Biomarker Discovery, Inc. Metabolic biomarkers of autism
WO2011140484A1 (en) 2010-05-06 2011-11-10 Singulex, Inc Methods for diagnosing, staging, predicting risk for developing and identifying treatment responders for rheumatoid arthritis
WO2012013758A2 (en) * 2010-07-28 2012-02-02 Abbott Gmbh & Co. Kg Method for detection of ischemic strokes
US20130338194A1 (en) * 2010-11-11 2013-12-19 Medical University Of South Carolina Predicting Atrial Fibrillation Recurrence by Protease and Protease Inhibitor Profiling
EP2492691A1 (en) 2011-02-22 2012-08-29 Institut de Recerca Hospital Universitari Vall d'Hebron Method of predicting the evolution of a patient suffering of a neurovascular disease
WO2012123299A1 (en) 2011-03-11 2012-09-20 Roche Diagnostics Gmbh Asc as marker for chronic obstructive pulmonary disease (copd)
ES2762451T3 (en) 2011-04-04 2020-05-25 Berg Llc Treatment of tumors of the central nervous system with coenzyme Q10
CN103502813B (en) 2011-05-09 2016-10-12 积水医疗株式会社 The immunological assay method of solubility LR11
RU2469332C1 (en) * 2011-10-12 2012-12-10 Государственное бюджетное образовательное учреждение высшего профессионального образования "Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова" Министерства здравоохранения и социального развития Российской Федерации Differential diagnostic technique for bronchial asthma
ES2824110T3 (en) 2011-10-17 2021-05-11 Hoffmann La Roche Troponin as a marker of intermittent atrial fibrillation
CA2856461C (en) * 2011-12-01 2020-08-18 F. Hoffmann-La Roche Ag Nt-proanp and nt-probnp for the diagnosis of stroke
ES2933570T3 (en) 2011-12-08 2023-02-10 Astute Medical Inc Methods and compositions for the diagnosis and prognosis of kidney injury and kidney failure
EP2597465A1 (en) * 2012-06-26 2013-05-29 Roche Diagniostics GmbH TnT and H-FABP for diagnosis of cardiac damage in infection
US9414752B2 (en) 2012-11-09 2016-08-16 Elwha Llc Embolism deflector
WO2014072500A1 (en) 2012-11-09 2014-05-15 Roche Diagnostics Gmbh Tnt based diagnosis of paroxysmal atrial fibrillation
CN107976547B (en) 2013-01-17 2020-08-25 阿斯图特医药公司 Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP2951318A4 (en) * 2013-02-01 2016-08-17 Univ West Virginia A biomarker algorithm for determining the time of stroke symptom onset and method
KR101494882B1 (en) 2013-02-21 2015-02-25 한국과학기술연구원 A composition for diagnosing acute myocardial infarction, a kit for diagnosing acute myocardial infarction comprising the composition, and a method for diagnosing acute myocardial infarction
BR112015025424A2 (en) 2013-04-08 2017-07-18 Berg Llc cancer treatment using coenzyme q10 combination therapies
GB201309928D0 (en) * 2013-06-04 2013-07-17 Randox Lab Ltd Method
US10534003B2 (en) * 2013-07-17 2020-01-14 The Johns Hopkins University Multi-protein biomarker assay for brain injury detection and outcome
WO2015028671A1 (en) * 2013-08-30 2015-03-05 Metanomics Gmbh Means and methods for diagnosing heart failure in a subject
AU2014315186B2 (en) 2013-09-04 2020-02-27 Berg Llc Methods of treatment of cancer by continuous infusion of coenzyme Q10
FR3010187A1 (en) * 2013-09-05 2015-03-06 Ct Hospitalier Universitaire Rouen USE OF UROTENSIN II AND / OR URP AS MARKERS FOR THE DIAGNOSIS OF POST HSA VASOSPASM
WO2015179773A1 (en) 2014-05-22 2015-11-26 The Scripps Research Institute Tissue molecular signatures of kidney transplant rejections
WO2015042465A1 (en) * 2013-09-20 2015-03-26 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of appendicitis and differentiation of causes of abdominal pain
CA2930790A1 (en) * 2013-11-15 2015-05-21 Christopher Joseph Pemberton Biomarker for cardiac disorders
US9176113B1 (en) 2014-04-11 2015-11-03 Synapdx Corporation Methods and systems for determining autism spectrum disorder risk
US20150294081A1 (en) 2014-04-11 2015-10-15 Synapdx Corporation Methods and systems for determining autism spectrum disorder risk
EP3146076A4 (en) 2014-05-22 2018-05-09 The Scripps Research Institute Gene expression profiles associated with sub-clinical kidney transplant rejection
US11104951B2 (en) 2014-05-22 2021-08-31 The Scripps Research Institute Molecular signatures for distinguishing liver transplant rejections or injuries
GB2538006A (en) 2014-05-22 2016-11-02 Scripps Research Inst Gene expression profiles associated with sub-clinical kidney transplant rejection
US10443100B2 (en) 2014-05-22 2019-10-15 The Scripps Research Institute Gene expression profiles associated with sub-clinical kidney transplant rejection
WO2016065202A1 (en) * 2014-10-22 2016-04-28 The George Washington University a Congressionally Chartered Not-for-Profit Corporation Blood biomarkers for appendicitis and diagnostics methods using biomarkers
US10525020B2 (en) 2015-02-11 2020-01-07 Laboratory Corporation Of America Holdings Metabolic markers of attention deficit hyperactivity disorder
US10690681B2 (en) 2015-03-06 2020-06-23 Washington University Methods to detect myocardial injury and uses thereof
WO2017067821A1 (en) * 2015-10-22 2017-04-27 Universite Pierre Et Marie Curie (Paris 6) A method for determining presence or risk of hemostasis disorder
KR101801092B1 (en) 2016-01-28 2017-11-28 순천향대학교 산학협력단 Composition for Idiopathic pulmonary fibrosis prognosis and method of providing the information for the same
US11243217B2 (en) 2016-06-06 2022-02-08 Astute Medical, Inc. Management of acute kidney injury using insulin-like growth factor-binding protein 7 and tissue inhibitor of metalloproteinase 2
CN108728525B (en) * 2017-04-19 2021-06-22 香港中文大学 Circulating microRNA biomarker for subarachnoid hemorrhage and application thereof
WO2018229051A1 (en) * 2017-06-13 2018-12-20 Roche Diagnostics Gmbh Fatty acid binding protein 3 for the assessment of atrial fibrillation (af)
EP3655545B1 (en) 2017-07-18 2023-10-18 The Research Foundation for The State University of New York Biomarkers for intracranial aneurysm
CN109975548B (en) * 2018-03-08 2020-08-07 中山大学 Application of IgG4 detection reagent in preparation of colorectal cancer diagnostic agent
WO2019189725A1 (en) * 2018-03-30 2019-10-03 国立研究開発法人国立精神・神経医療研究センター Neonatal hypoxic-ischemic encephalopathy severity determining method and prognosis predicting method
EP3553524A1 (en) * 2018-04-12 2019-10-16 Koninklijke Philips N.V. Periodontitis diagnostic methods, uses and kits
EP3553518A1 (en) * 2018-04-12 2019-10-16 Koninklijke Philips N.V. Periodontitis diagnostic methods, uses and kits
EP3553525A1 (en) * 2018-04-12 2019-10-16 Koninklijke Philips N.V. Diagnostics of mild or advanced periodontitis
EP3553520A1 (en) * 2018-04-12 2019-10-16 Koninklijke Philips N.V. Methods, uses and kits for monitoring or predicting response to periodontal disease treatment
JP7398226B2 (en) 2019-09-03 2023-12-14 浜松ホトニクス株式会社 Methods for assessing the risk of developing colorectal cancer
JPWO2021199792A1 (en) * 2020-04-02 2021-10-07
CN113791219B (en) * 2020-07-24 2022-08-02 首都医科大学附属北京天坛医院 Biomarker for acute ischemic stroke recurrence risk analysis and application thereof
CN113252910B (en) * 2021-06-29 2022-05-17 中国人民解放军军事科学院军事医学研究院 Application of TIMP3 in anxiety and depression diagnosis
CN115287346A (en) * 2022-05-26 2022-11-04 中山大学深圳研究院 Acute myocardial infarction early detection marker and detection kit
CN116059328A (en) * 2022-09-14 2023-05-05 深圳先进技术研究院 Application of TIMP3 recombinant protein in preparation of preparation for inhibiting hypertensive renal clear cell carcinoma

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5599668A (en) * 1994-09-22 1997-02-04 Abbott Laboratories Light scattering optical waveguide method for detecting specific binding events
US6214560B1 (en) * 1996-04-25 2001-04-10 Genicon Sciences Corporation Analyte assay using particulate labels
WO2003016910A1 (en) * 2001-08-20 2003-02-27 Biosite, Inc. Diagnostic markers of stroke and cerebral injury and methods of use thereof
US20030153014A1 (en) * 1999-10-08 2003-08-14 Li Shen Compositions and methods for detecting protein modification and enzymatic activity

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5604105B1 (en) * 1990-10-12 1999-08-24 Spectral Diagnostics Inc Method and device for diagnosingand distinguishing chest pain in early onset thereof
CA2263063C (en) * 1999-02-26 2004-08-10 Skye Pharmatech Incorporated Method for diagnosing and distinguishing stroke and diagnostic devices for use therein
AUPR005600A0 (en) * 2000-09-12 2000-10-05 University Of Sydney, The Diagnostic assay
US7632647B2 (en) * 2001-04-13 2009-12-15 Biosite Incorporated Use of B-type natriuretic peptide as a prognostic indicator in acute coronary syndromes
ATE439588T1 (en) * 2001-05-04 2009-08-15 Biosite Inc DIAGNOSTIC MARKERS FOR ACUTE HEART DISEASE AND METHODS OF USE

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5599668A (en) * 1994-09-22 1997-02-04 Abbott Laboratories Light scattering optical waveguide method for detecting specific binding events
US6214560B1 (en) * 1996-04-25 2001-04-10 Genicon Sciences Corporation Analyte assay using particulate labels
US20030153014A1 (en) * 1999-10-08 2003-08-14 Li Shen Compositions and methods for detecting protein modification and enzymatic activity
WO2003016910A1 (en) * 2001-08-20 2003-02-27 Biosite, Inc. Diagnostic markers of stroke and cerebral injury and methods of use thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1587955A4 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7838250B1 (en) 2006-04-04 2010-11-23 Singulex, Inc. Highly sensitive system and methods for analysis of troponin
US8343728B2 (en) 2006-04-04 2013-01-01 Singulex, Inc. Highly sensitive system and method for analysis of troponin
US8535895B2 (en) 2006-04-04 2013-09-17 Singulex, Inc. Highly sensitive system and method for analysis of troponin
US9182405B2 (en) 2006-04-04 2015-11-10 Singulex, Inc. Highly sensitive system and method for analysis of troponin
US9494598B2 (en) 2006-04-04 2016-11-15 Singulex, Inc. Highly sensitive system and method for analysis of troponin
US8221995B2 (en) 2007-03-23 2012-07-17 Seok-Won Lee Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes
US8450069B2 (en) 2009-06-08 2013-05-28 Singulex, Inc. Highly sensitive biomarker panels

Also Published As

Publication number Publication date
EP1587955A4 (en) 2007-03-14
AU2003302340B2 (en) 2008-08-21
EP1587955A2 (en) 2005-10-26
WO2004059293A2 (en) 2004-07-15
AU2003302340B8 (en) 2008-09-11
CA2511501A1 (en) 2004-07-15
JP2006526140A (en) 2006-11-16
AU2003302340A1 (en) 2004-07-22

Similar Documents

Publication Publication Date Title
WO2004059293A3 (en) Markers for differential diagnosis and methods of use thereof
WO2002042775A3 (en) Clinically intelligent diagnostic devices and methods
WO2005027733A3 (en) Biological markers for diagnosing multiple sclerosis
WO2003000853A3 (en) Protein aggregation assays and uses thereof
WO2006071247A3 (en) Diagnostic assays including multiplexed lateral flow immunoassays with quantum dots
WO2002089657A3 (en) Diagnostic markers of acute coronary syndromes and methods of use thereof
MXPA04000062A (en) Homocysteinylated transthyretin.
WO2005058961A3 (en) Antibodies specific for human galanin, and uses thereof
WO2004048598A3 (en) Molecular nephrotoxicology modeling
WO2003023573A3 (en) Patient classification
WO2002095000A3 (en) Molecular toxicology modeling
BRPI0114343B8 (en) method for detecting immunoglobulin ige and for in vitro diagnosis of allergies, as well as microarray chip and kit comprising it
WO2004063753A3 (en) A serum marker for measuring liver fibrosis
WO2006128042A3 (en) Methods of identifying mutations in nucleic acid
WO2006024466A3 (en) Test device for the in vitro diagnosis of multi-analyte tests and the use thereof
WO2004067570A3 (en) Prostate cancer diagnosis and treatment
WO2009126969A3 (en) Biomarkers for endometrial disease
WO2004007743A3 (en) Use of cpg nucleic acids in prion-disease
WO2007132120A3 (en) Procedure and methods for detecting alzheimer's disease
WO2002086448A3 (en) Detection of microsatellite instability and its use in diagnosis of tumors
WO2007000320A3 (en) Method for diagnosing rheumatic diseases
WO2006099543A3 (en) Methods for assessing antibody-mediated cytotoxicity
WO2007109733A3 (en) Diagnostic and prognostic markers and treatment strategies for multiple sclerosis
BR0014150A (en) Diagnostics and therapeutics for osteoporosis
WO2007061988A3 (en) Methods for determining notch signaling and uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2511501

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 169348

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2005510072

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 3018/DELNP/2005

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2003302340

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2003810896

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 20038A98399

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2003810896

Country of ref document: EP